Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–13 of 13 results
Advanced filters: Author: Remo Panaccione Clear advanced filters

  • An analysis of data from 522 population-based studies encompassing 82 global regions and spanning more than a century (1920–2024) shows spatiotemporal transitions across epidemiologic stages 1 to 3 of inflammatory bowel disease, and models stage 4 progression.

    • Lindsay Hracs
    • Joseph W. Windsor
    • Gilaad G. Kaplan
    ResearchOpen Access
    Nature
    Volume: 642, P: 458-466

  • A 38-year-old female was evaluated for a 3 year history of postprandial abdominal pain, refractory nausea, vomiting and hematemesis. Her medical history was significant for juvenile polyposis syndrome and Crohn's disease resulting in a total colectomy. Juvenile polyposis syndrome with outlet obstruction of the stomach and excessive hypergastrinemia was diagnosed and treatment started with acid suppressive therapy, prokinetic therapy and total parenteral nutrition. Repetitive endoscopic polypectomy (also known as debulking) was performed twice followed by gastrectomy with duodeoesophageal anastomosis.

    • Karen D. Papay
    • Vincent G. Falck
    • Martin A. Storr
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 7, P: 583-588

  • Despite the widespread use of biologic therapy for IBD, safety concerns still exist. To realize the full potential of these therapies it is important to select appropriate patients for therapy and to optimize the delivery of these agents, thus maximizing their effectiveness. At the same time it is important to adopt strategies before and during treatment that minimize the occurrence of adverse effects. This Review outlines the adverse events associated with biologic therapies, and gives recommendations on how to reduce the risk of these events.

    • Shanika de Silva
    • Shane Devlin
    • Remo Panaccione
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 7, P: 93-101

  • Inflammatory bowel disease (IBD) is an immune-mediated disease with substantial burden worldwide. In this Consensus Statement, a global multidisciplinary group of experts identify key priorities and recommendations to raise awareness and advance IBD care and research.

    • Virginia Solitano
    • Charles N. Bernstein
    • Silvio Danese
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 22, P: 438-452

  • Kenneth Croitoru, Andrew Paterson and colleagues perform genome-wide association analysis for gut microbiome composition. They identify 58 SNPs significantly associated with relative abundance of 33 taxa and replicate 4 of the associations in an independent cohort, providing further evidence that host genetics can influence the gut microbiota.

    • Williams Turpin
    • Osvaldo Espin-Garcia
    • Kenneth Croitoru
    Research
    Nature Genetics
    Volume: 48, P: 1413-1417

  • Crohn’s disease is a progressive, destructive inflammatory bowel disease of unclear cause and involves chronic inflammation of any part of the gastrointestinal tract. This Primer reviews the epidemiology, pathophysiology, diagnosis and management of this disease.

    • Giulia Roda
    • Siew Chien Ng
    • Silvio Danese
    Reviews
    Nature Reviews Disease Primers
    Volume: 6, P: 1-19

  • Anachebe et al. discuss how to center equity in medical school admissions by presenting an equity-based framework that focuses on recruiting, standards, selection and support. Their recommended strategies are universally applicable across training programs and are accompanied by a number of promising examples.

    • Ngozi F. Anachebe
    • Leila Amiri
    • Kenneth Royal
    Comments & OpinionOpen Access
    Communications Medicine
    Volume: 4, P: 1-5